​

Savara Stock (NASDAQ:SVRA)

ForecastOwnershipFinancialsChart
Savara by TradingView

Previous Close

$4.93

52W Range

$1.98 - $7.00

50D Avg

$5.29

200D Avg

$5.01

Market Cap

$1.04B

Avg Vol (3M)

$1.57M

Beta

0.27

Div Yield

-

SVRA Company Profile

Savara Inc. is a biopharmaceutical firm in the clinical development phase, specializing in therapies for uncommon respiratory conditions. Their primary investigational drug, molgramostim, is an inhaled form of granulocyte-macrophage colony-stimulating factor (GM-CSF). This compound is currently undergoing Phase III trials to address autoimmune pulmonary alveolar proteinosis. The company's main operations are situated in Austin, Texas.

Show More

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

-

Country

US

Employees

59

IPO Date

Apr 28, 2017

Website

SVRA Performance

SVRA Financial Summary

Dec 25Dec 24Dec 23
Revenue---
Operating Income$-123.55M$-103.20M$-60.01M
Net Income$-118.84M$-95.88M$-54.70M
EBITDA$-123.46M$-102.27M$-59.13M
Basic EPS$-0.53$-0.48$-0.33
Diluted EPS$-0.53$-0.48$-0.33

Fiscal year ends in Dec 25 | Currency in USD

Latest Earnings Call Transcripts

Q2 20Aug 06, 20 | 4:30 PM
Q1 20May 07, 20 | 4:30 PM
Q4 19Mar 12, 20 | 4:30 PM

Peer Comparison

TickerCompany
TNGXTango Therapeutics, Inc.
EYPTEyePoint Pharmaceuticals, Inc.
NBTXNanobiotix S.A.
KURAKura Oncology, Inc.
BCAXBicara Therapeutics Inc. Common Stock
RZLTRezolute, Inc.
GHRSGH Research PLC
TYRATyra Biosciences, Inc.
PROKProKidney Corp.
GERNGeron Corporation